Author:
Azria D.,Auvray H.,Barillot I.,Baumann P.,Benyoucef A.,Bons-Rosset F.,Bontemps P.,Bourgier C.,Breton-Callu C.,Cowen D.,Cretin J.,Delalande B.,Denis F.,Ellis S.,Gaci Z.,Hannoun-Lévy J.-M.,Hasbini A.,Hennequin C.,Lagrange J.-L.,Lartigau E.,Latorzeff I.,Le Blanc-Onfroy M.,Lecouillard I.,Lemanski C.,Levy C.,Maingon P.,Marchal C.,Monnier A.,Pradier O.,Racadot S.,Romestaing P.,Serin D.,Simon J.-M.,Teyssier E.,Tallet A.,Tolédano A.,Belkacémi Y.
Subject
Radiology, Nuclear Medicine and imaging,Oncology
Reference22 articles.
1. Concomitant use of tamoxifen with radiotherapy enhances subcutaneous breast fibrosis in hypersensitive patients;Azria;Br J Cancer,2004
2. Azria D, Ozsahin M, Kramar A, Peters S, Atencio DP, Crompton NE, et al. Single nucleotide polymorphisms, apoptosis and the development of severe late adverse effects following radiotherapy. Clin Cancer Res; in press
3. Ductal in situ carcinoma: is it ethical to consider the breast conserving therapy as a standard?;Barillot;Cancer Radiother,2004
4. Breast-Conserving Treatment With or Without Radiotherapy in Ductal Carcinoma-In-Situ: Ten-Year Results of European Organisation for Research and Treatment of Cancer Randomized Phase III Trial 10853—A Study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group
5. Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853;Bijker;J Clin Oncol,2001